BioChaperone® Glucagon
Severe Hypoglycemia
Phase 1Active
Key Facts
About Adocia
Adocia, founded in 2005, is a French public biotech company specializing in metabolic diseases, particularly diabetes and obesity. It operates a 'license-out' business model, advancing proprietary products through clinical proof-of-concept before partnering with larger pharmaceutical firms. The company's pipeline is built on four core technology platforms—BioChaperone®, AdoShell®, AdOral®, and AdoXLong—with candidates ranging from Phase 1 to Phase 3. While pre-revenue from product sales, Adocia finances operations through equity fundraising and partnership milestones.
View full company profileOther Severe Hypoglycemia Drugs
| Drug | Company | Phase |
|---|---|---|
| Gvoke (glucagon) | Xeris Pharmaceuticals | Approved |
| Ogluo | Xeris Pharmaceuticals | Approved |